Key facts
- Evolyzer’s last known valuation is $20.7M (Feb 2025).
- It has raised $28.5M; the latest was Early Stage VC in Feb 2025.
- Notable investors include HSG (Hong Kong), CDH Investments, TusStar Incubator, Frees Fund, Tsinghua Innovation Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Evolyzer
- ·The full record, as it builds
Funding rounds
No funding rounds for Evolyzer are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evolyzer
Manufacturer of industrial biocatalyst designed for agriculture, oil fields and daily chemicals industries. The company offers industrial biocatalyst, synthetic biology and bio-nanotechnology research, thereby enabling manufactory to use high-efficiency and high-resistance biocatalyst.
- Sector
- Materials and Resources
- HQ
- Beijing, China
- Founded
- 2022
- Employees
- 78
- Website
- evolyzer.com/
- Ownership
- Privately Held (backing)
Evolyzer doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evolyzer shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evolyzer in its N-PORT filings yet. We sweep new filings monthly.